Skip to Main Content

Paper Details

Utilizing metformin to prevent metabolic syndrome due to androgen deprivation therapy (ADT): a randomized phase II study of metformin in non-diabetic men initiating ADT for advanced prostate cancer.
Oncotarget
0
2023
AMPK, Androgen, MS, Metformin, PC, PSA, advanced prostate cancer, androgen, diabetic, glucose, insulin, mTOR, men, metabolic syndrome, metformin, patients, phospho-S6 kinase, phospho-S6-kinase
Author NameAffiliation
Joel E MichalekUniversity of Texas Health Science Center
Joel E MichalekUniversity of Texas Health Science Center
John G KuhnUniversity of Texas Health Science Center
Ian M ThompsonUniversity of Texas Health Science Center
Ian M Thompson
  • 1 - 5

Datasets

Release 1.2